𧬠Testing Methodology
Credits: Dr. Mohammad Al-Shinnag, KFSHRC
π¬ Sample Type
𧬠Suspected Inherited Disorders (Germline Testing)
π©Έ Peripheral blood
π§« Skin fibroblasts
π Hair follicles
π Buccal swabs
π Requires dedicated non-tumor tissue for accurate germline analysis.
π©Έ Cancer Diagnostic and Assessment Workup (Somatic Testing)
π§« Tumor tissue
𧬠Cancer cells
π©Έ Peripheral blood
𦴠Bone marrow
π Essential for diagnosis, prognosis, and therapeutic decision-making.
βοΈ Testing Methods
π§ͺ Chromosomal Analysis
𧬠Karyotyping β Detects large structural abnormalities and aneuploidy.
π¬ FISH (Fluorescence In Situ Hybridization) β Identifies specific gene rearrangements and copy number changes.
π Microarray (aCGH/SNP Array) β Detects submicroscopic deletions and duplications.
𧬠Molecular Analysis
π§ͺ Next-Generation Sequencing (NGS) β Comprehensive mutation profiling.
π Sanger Sequencing β Gold standard for variant confirmation.
π§© Fragment Analysis β Detects insertions, deletions, and repeat expansions.
π PCR-Based Assays/RT-PCR β Targeted detection and quantification of variants.
π Sensitivity and Limit of Detection (LOD)
π― Purpose of Testing
π Diagnostic Testing β Identifies disease-causing variants.
π Prognostic and Management Testing β Guides risk stratification and therapy.
π Approximate Sensitivity by Method
𧬠Karyotyping: ~5β10% clone detection.
π¬ FISH: ~1β5%.
π§ͺ NGS: ~1β5% (β€1% with ultra-deep sequencing).
π§« RT-qPCR/ddPCR: up to 10β»β΄β10β»βΆ for MRD assessment.
π©Έ Clinical Relevance in Hematology
π¬ AML: NPM1, FLT3, IDH1/2 mutations.
𧬠CML: BCR::ABL1 detection and monitoring.
π©Έ MDS: Cytogenetic abnormalities and somatic mutations.
π§« ALL: Fusion genes and MRD assessment.
𧬠Myeloma: Copy number alterations and translocations.
π― Key Takeaway
π Optimal test selection depends on clinical context, specimen type, disease mechanism, and required sensitivity, forming the cornerstone of precision hematology.
#MolecularGenomics #TestingMethodology #PrecisionMedicine #NGS #FISH #Cytogenetics #Hematology #KFSHRC